Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 261-280 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 261 | Agnikul Cosmos lowweak | Opp 1 Risk 1 | Thesis: Insufficient admissible reviewed sources evidence to form a positive thesis within the selected recent evidence window. Membership rationale says the company is a rocket startup raising funding and planning an orbital debut, but no surviving article/evidence are provided for direct support. Why now: Why now is unsupported because the reviewed sources show zero evidence after recent evidence filtering despite many articles considered; recency-specific business state cannot be established from the provided evidence. Caveats: Coverage debug shows zero evidence after recent evidence filtering. Membership rationale cannot substitute for cited directional evidence under the output rules. Absence of evidence is not positive or negative proof. |
| 262 | Airbus SE lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources gives only weak context that Airbus was listed in a satellite-servicing landscape, which is insufficient on its own to support a strong positive thesis for a 1 year+ horizon. Why now: There is no within the recent evidence window evidence available for Airbus; the only cited article is older context published March 4, 2025, outside the 90-day cutoff noted by the reviewed sources, so recency support is weak. Caveats: Coverage after recent evidence window is effectively empty: articles after recent evidence window is 0. The available Airbus article is contextual and outside the 90-day recent evidence window. Cohort membership does not establish attractiveness. |
| 263 | Alta Ares lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable because the retained reviewed sources contain no direct positive evidence after recent evidence window. Why now: Why now is weak: the reviewed sources show no retained evidence after recent evidence window, and the membership rationale says Alta Ares appears only in a broad funding roundup without enough company-specific detail. Caveats: Phase-2 membership rationale references: but no article summary or direct retained evidence is available here for factual use. The reviewed sources itself says company-specific detail is insufficient. |
| 264 | Altamira Technologies Corporation lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable because the reviewed sources does not provide direct positive evidence or article summaries for Altamira in the scoring section. Why now: The phase2 rationale notes only that Parsons acquired Altamira and references defense/national security themes, but no citable evidence are provided here. Coverage data shows zero articles after recent evidence window and zero evidence available. Caveats: Ownership/acquisition context alone is not enough without direct evidence detail. No dated catalyst evidence is surfaced in the reviewed sources. |
| 265 | Amazon.com Inc. lowweak | Opp 1 Risk 1 | Thesis: The membership rationale references satellite and direct-to-device ambitions, but the reviewed sources contain no within the recent evidence window evidence or representative article summaries to support a current space-related opportunity thesis here. Why now: No current catalyst can be established from the available evidence because post-recent evidence window evidence are absent. Caveats: Extremely large mention universe is not conviction. No usable evidence were available after recent evidence window. |
| 266 | AnduraX lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources' membership rationale says AnduraX is developing a reusable spaceplane and has VC backing, but no retained within the recent evidence window article evidence is available here to support an opportunity thesis. Why now: There is no retained article or evidence row after the 90-day recent evidence window, so the reviewed sources does not establish a current catalyst or updated business state. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article IDs, and: but no or retained summaries are provided here. Scores remain low because positive or negative direction cannot be grounded with citable retained evidence. |
| 267 | Angkasa-X Holdings Corp. lowweak | Opp 1 Risk 1 | Thesis: No retained within the recent evidence window direct positive evidence is provided in the reviewed sources, so there is not enough support for a positive 1 year+ thesis. Why now: There is no usable within the recent evidence window article evidence available for ranking; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency-sensitive judgment is not possible from these reviewed sources alone. Caveats: Reviewed evidence notes one considered article for membership support but zero article IDs after recent evidence window and zero available evidence after recent evidence window, so ranking is constrained by evidence absence rather than business absence. Membership rationale references article: but the reviewed sources does not provide the article or a retained within the recent evidence window evidence row for ranking use. |
| 268 | Applied Aerospace & Defense Inc. lowweak | Opp 1 Risk 1 | Thesis: There is insufficient company-specific positive evidence in the reviewed sources to support an opportunity thesis. The only cited context is that the company was referenced as competition in a space-sector article and that the reviewed sources notes a $650M IPO, but no direct business traction, contract, product, or financial evidence within the recent evidence window is available (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources show zero evidence available after the 90-day recent evidence window cutoff date of March 29, 2026, so recency-based catalysts cannot be established from these reviewed sources. Caveats: No current evidence is provided for cited Evidence rows available after recent evidence window: 0. Mention as competition or IPO context is weaker than direct company event evidence. |
| 269 | Argotec lowweak | Opp 1 Risk 2 | Thesis: There is not enough kept recent evidence window evidence in these reviewed sources to form a positive 1 year+ thesis beyond weak historical cohort relevance. Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, and the only cited support is an older membership rationale referring to 7 Hawk microsatellites for Italy's IRIDE constellation aboard a SpaceX launch from article: but no article or dated evidence row is provided in the reviewed sources for ranking use. Caveats: No article is provided for the membership support article: so it cannot be cited as a factual ranked-evidence item under the the evidence standard. Coverage debug shows zero evidence after recent evidence window. Private/public status is not used as a filter and is unclear from these reviewed sources. |
| 270 | ArianeGroup lowweak | Opp 1 Risk 1 | Thesis: ArianeGroup appears relevant to launch services in the phase2 rationale, but the reviewed sources provide no direct positive evidence or citable representative summaries for a ranked positive thesis. Why now: The phase2 rationale references Ariane 6/Arianespace launch context for Amazon Kuiper, but relation/context evidence cannot be used as counterparty propagation and no direct evidence is exposed in the scoring fields. Coverage data shows zero articles after recent evidence window and zero evidence available. Caveats: Do not use context-only relation logic as direct thesis proof. No direct company-specific event evidence is included here. |
| 271 | Arxis, Inc. lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supported within the retained 90-day evidence window; the reviewed sources only shows older cohort-membership context identifying Arxis as a small satellite manufacturer from article, but no in-window direct positive event or fact is available. Why now: Why now is unclear because coverage data shows 0 articles after recent evidence window and 0 evidence after recent evidence window, so there is no retained recent catalyst evidence in the reviewed sources. Caveats: Reviewed evidence cites membership support from, but no representative article is provided, so the underlying claim cannot be restated as direct scored evidence with. Coverage after recent evidence window is empty, limiting conviction. |
| 272 | Arxis Inc. lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable from the retained reviewed sources evidence because no direct positive evidence survived the 90-day recent evidence window. Why now: Why now is weak: the reviewed sources show zero evidence after recent evidence window for Arxis Inc., so there is no current catalyst or current business-state proof in the retained record. Caveats: Coverage after recent evidence window is empty for this company. Phase-2 membership rationale references support references including: but no article summary or quoted evidence is included in the retained reviewed sources, so it cannot be used for factual claims here. |
| 273 | Aselsan lowweak | Opp 1 Risk 1 | Thesis: No retained in-recent evidence window evidence supports a current positive thesis, even though the membership rationale notes LUNA-2 nanosatellite activity. Why now: The reviewed sources retained zero evidence after the 90-day cutoff, so there is no current catalyst evidence for the 1 year+ ranking despite article-based membership context. Caveats: Membership rationale cites article, but no article summary or retained evidence row is available here. 24 articles were considered, but none remained after recent evidence filtering. |
| 274 | Astranis Space Technologies lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence rationale references selection under the U.S. Space Force Andromeda program, which could be strategically positive, but no retained evidence are present here to support ranking it higher. Why now: No retained article or facts remain in the reviewed sources after recent evidence window, so timing and durability cannot be judged from local evidence. Caveats: Opportunity view depends on uncited membership rationale rather than retained evidence. No recency-confirmed direct evidence in reviewed sources. |
| 275 | Astro Digital lowweak | Opp 1 Risk 1 | Thesis: No strong positive thesis is supported. The reviewed sources only says Astro Digital was named as one of Star Catcher's signed power purchase agreement counterparties, implying operation of satellites or space assets, but this is counterparty context from a single article and not sufficient as direct positive evidence (: no provided in reviewed sources). Why now: No supported current catalyst. The reviewed sources explicitly warns this is counterparty context only, and coverage debug shows no retained evidence after recent evidence window. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Counterparty context should not be treated as strong propagation evidence. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 276 | Astrobiome Space lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable from retained evidence in these reviewed sources because no direct positive rows survive the recent evidence window. Why now: There is no retained evidence showing a current contract milestone, financing event, or product progress inside the recent evidence window. Caveats: Phase-2 rationale says Astrobiome Space contracted Redwire for a commercial space greenhouse/ISS agriculture mission and cites: and: but no or summaries are available here. Coverage debug shows 6 articles considered and 0 after recent evidence window. Relationship context should not be propagated as stronger evidence without direct retained event/facts. |
| 277 | Axiom Space lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable from within the recent evidence window evidence in these reviewed sources. The only cited article is an older external article noting Axiom previously received a NASA commercial space station contract, but it is dated September 2, 2025 and falls outside the reviewed sources' 90-day recent evidence window, so it cannot support a current opportunity call. Why now: There is no within the recent evidence window catalyst in the available evidence. The only cited context is an older article with September 2, 2025, outside the 90-day evidence window Caveats: Coverage after recent evidence window is effectively empty: evidence after recent evidence window is 0. Older supporting context exists but was excluded by the 90-day recent evidence window. No direct positive or negative evidence is available. |
| 278 | Axiom Space Inc. lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable because the reviewed sources provide no direct positive evidence or citable representative article summaries in the final evidence fields. Why now: The phase2 rationale says Axiom was mentioned in connection with a lunar suit presentation and an orbital data center feature, but those article details are not surfaced in citable evidence here. Coverage data shows zero articles after recent evidence window and zero available evidence, so there is no current catalyst basis in the reviewed sources. Caveats: Phase2 rationale is weaker than direct event/fact evidence. No dated current-state evidence is available in the scoring fields. |
| 279 | BAE Systems plc lowweak | Opp 1 Risk 1 | Thesis: There may be a space-related opportunity because the membership rationale says BAE Systems was selected by the U.S. Space Force for the Andromeda program, but the reviewed sources does not load the underlying within the recent evidence window evidence or article summaries needed to support a directional thesis. Why now: Why-now is weak because the reviewed sources show no reviewed evidence after recent evidence window despite many articles considered, leaving no admissible dated evidence in the current output batch. Caveats: Membership rationale references, and, but no article summaries or evidence are provided here. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Broad-company membership in a cohort is not itself a directional opportunity thesis. |
| 280 | Baykar lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable because the retained reviewed sources provide no direct positive evidence for Baykar within the recent evidence window. Why now: Why now is weak: there are no retained evidence after recent evidence window, and the reviewed sources' membership rationale is based only on weak indirect article context. Caveats: Phase-2 membership rationale cites and says Fergani Space was described as 'Baykar affiliated,' but no article summary or quote is available in the retained reviewed sources for factual use here. The reviewed sources itself characterizes the evidence as weak, indirect article context. |
Risk view
Showing rows 81-100 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 81 | Interlune lowweak | Opp 5 Risk 3 | Thesis: The company also carries execution risk because the reviewed sources provide no further retained evidence on milestone completion, follow-on awards, commercialization timing, or technical results. A single contract supports relevance but does not prove scalable economics. Why now: The key 'why now' is the cited NASA contract in article: but the reviewed sources does not include the article summary or, so exact date and latest status are not visible here. Caveats: Opportunity case relies on membership rationale rather than included direct article evidence. A $6.9M contract is positive validation, but contract size alone may not be enough to de-risk a lunar-resource business. No negative evidence is provided, so risk mostly reflects execution uncertainty. |
| 82 | IonQ lowweak | Opp 3 Risk 3 | Thesis: Risk stems from thesis leakage: the reviewed sources frames IonQ primarily as parent/acquirer, while the strongest space-specific evidence appears to sit at subsidiary level, so investors could overstate IonQ's direct space-business impact based on insufficient company-specific proof. Why now: Potential 'why now' would be the referenced space-subsidiary contract pathway, but recency and direct materiality to IonQ are not validated in available evidence for the 90-day recent evidence window. Caveats: Phase-2 rationale references and: but no or summaries are provided in the reviewed sources. Relations and counterparty propagation are not allowed by default. Coverage debug shows zero evidence after recent evidence window despite a large article universe. |
| 83 | Iridium Communications Inc. lowmedium | Opp 5 Risk 3 | Thesis: Risk is moderate-low because there is no direct adverse evidence, but the reviewed sources lack recent company-specific contract, financing, or product milestone catalysts, so the case depends more on strategic position than on fresh business acceleration. Why now: The current support is an April 3, 2026 article-level overview of Iridium’s constellation and service footprint rather than a new event, so timing fit is only medium. Evidence
Caveats: Evidence is supporting article context, not a fresh contract or earnings-linked milestone. |
| 84 | Kepler mediummedium | Opp 6 Risk 3 | Thesis: Risk remains moderate because the evidence is primarily a company-source article and supporting article context rather than independent dated event evidence. The reviewed sources show no adverse developments, but also limited third-party confirmation. Why now: The latest visible evidence is dated June 23, 2026, making the milestone recent within the 90-day recent evidence window. The article explicitly frames this as the beginning of an operational network, which is more relevant to a 1 year+ horizon than a short-lived announcement. Evidence
Caveats: Primary evidence is from Kepler's own site. No direct contract, revenue, or financing detail is provided in the visible evidence. Same article appears in both representative and weak-context forms, which is not independent confirmation. |
| 85 | Kepler Aerospace lowweak | Opp 3 Risk 3 | Thesis: There is no direct negative evidence available. The main risk is that the business description is broad but unsupported by current, citable post-recent evidence window evidence, leaving commercialization and scale uncertain. Why now: No current catalyst is established. Membership support references article ID: but the reviewed sources provide no and shows no evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary. Context includes relation/fact counts in support statistics, but relations are context-only and cannot be propagated as operating proof. |
| 86 | L3Harris Technologies mediummedium | Opp 6 Risk 3 | Thesis: Risk is lower than many peers in these reviewed sources because there is no cited direct adverse evidence, but the ranking is capped by limited fresh company-specific evidence within the 90-day window and reliance on supporting article context rather than detailed award economics attributable specifically to L3Harris. Why now: The recent timing anchor is the April 8, 2026 Andromeda article. Older 2020 MOSSAIC history exists in the reviewed sources but should not drive the current timing view because it is outside the recent evidence window and materially older than the current contract context. Evidence
Caveats: Current opportunity case depends on supporting article context rather than available direct positive events. The reviewed sources includes an older 2020 contract article, but that is not recent support for 'why now'. |
| 87 | Loft Orbital mediummedium | Opp 7 Risk 3 | Thesis: Risk exists because the positive case is largely supporting article context from external supporting source sources rather than direct dated events in the reviewed sources, and execution remains significant given a 10-satellite constellation deployment and launch timeline. But there is no retained material adverse evidence. Why now: Why now is credible for a 1 year+ horizon because several dated articles from 2026 establish a recent contract win and near-forward deployment timeline: Loft announced on April 30, 2026 a multi-year CNES contract worth up to tens of millions of euros with first satellite scheduled to launch in Q4 2026. Via Satellite on May 1, 2026 described a 10-satellite EO constellation under that contract. SpaceNews on May 5, 2026 said Loft is expanding into 'full-service constellation deals'. Evidence
Caveats: Most retained support is supporting article context, which the reviewed sources treats as bounded context and weaker than direct dated event/fact evidence. Several favorable funding articles for Loft are dated January 2025 and were dropped by the 90-day recent evidence window, so they should not drive the current score. Execution risk remains around deploying the constellation and meeting the stated 2026 launch timing. |
| 88 | MDA Space Ltd. lowweak | Opp 4 Risk 3 | Thesis: Risk is moderate because the available evidence is entirely undated external article context, making recency and state-of-business uncertain. Why now: Why-now is weak because both available representative articles are undated, so current timing and whether these items remain incremental versus already absorbed is uncertain Evidence
Caveats: Both cited articles are undated; recency is uncertain. Support is weak and based on article context, not direct positive events. No material adverse evidence is available, but no strong current catalyst is validated either. |
| 89 | Modul8 lowweak | Opp 4 Risk 3 | Thesis: Risk remains moderate because the reviewed sources supplies no available positive evidence after recent evidence window to confirm timing, contract status, or deployment progress; mission-heavy lunar communications programs can be timing-sensitive, but these reviewed sources gives no adverse proof either. Why now: Among sparse names, the stated combination of funding plus lunar communications program exposure could matter over 1 year+, but recency cannot be validated from served evidence. Caveats: The strongest claims are only in membership rationale and not backed by citeable -bearing evidence in the reviewed sources. No negative evidence does not equal low fundamental risk. |
| 90 | Muon Space lowweak | Opp 3 Risk 3 | Thesis: Risk is balanced with opportunity because the available evidence is mostly weak supporting article context rather than direct contract, financing, or milestone evidence, leaving business traction and near-medium term scaling uncertain. Why now: The most recent dated context is a May 22, 2026 job posting indicating contracting and legal operations needs, which may imply organizational buildout but is weak evidence for a major catalyst. Evidence
Caveats: The reviewed sources contain no direct positive or negative company-specific events. The May 22, 2026 job posting is operational context, not proof of revenue or contracts. Citation |
| 91 | NordSpace Corp. lowweak | Opp 3 Risk 3 | Thesis: No direct adverse evidence is available, but development-stage rocket businesses carry obvious execution dependency; in these reviewed sources that risk cannot be upgraded to high because the evidence does not show a specific setback, only insufficient current confirmation. Why now: The only directional clue is the membership-support article reference: but the reviewed sources includes no, no summary, and no available post-recent evidence window evidence, so timing and durability are uncertain. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary. Opportunity case relies on generic funding support mention without current milestone evidence. |
| 92 | Northrop Grumman Corp mediumstrong | Opp 8 Risk 3 | Thesis: Risk is present but comparatively modest in the reviewed sources because no material adverse event is cited. The main risk is that the evidence is largely supporting article context and program participation, so exact economic contribution, timing, and competitive share are not fully established here. Why now: The setup is current and cumulative: April 8, 2026 Andromeda participation, June 1, 2026 Golden Dome interceptor partnership, and June 22, 2026 award of a $398M protected satcom contract all fall within the 90-day recent evidence window and point to sustained momentum. Evidence
Caveats: The reviewed sources does not provide direct business impact breakdowns beyond the $398M contract article. Some support is supporting article context rather than dated events. |
| 93 | NorthStar Earth & Space lowweak | Opp 4 Risk 3 | Thesis: Risk is moderate because evidence coverage is very thin, and the reviewed sources offers mainly context that the company planned to go public via SPAC, without stronger direct proof on operational milestones or contract conversion in this company row. Why now: The only dated evidence in this row is an April 27, 2026 article-level summary stating NorthStar Earth & Space plans to go public in a SPAC deal at a $300 million valuation. That may matter over a 1 year+ horizon, but the reviewed sources does not provide stronger company-specific direct evidence here. Evidence
Caveats: Coverage is extremely thin in this row: only one external article and no direct positive or negative dated events. The phase-2 rationale mentions a CAD$40M+ Royal Canadian Air Force contract, but that contract evidence is not directly surfaced in the available evidence fields for this output row, so it should not be elevated beyond the membership rationale. |
| 94 | Open Cosmos mediummedium | Opp 7 Risk 3 | Thesis: Risk is present but not strongly evidenced as negative news. The main risks are that the evidence is supporting article context rather than direct events, and one supporting item concerns spacecraft supply to a military mission rather than direct revenue or contract award to Open Cosmos. Why now: The timing is favorable for a 1 year+ horizon because the latest dated evidence on June 17, 2026 indicates market entry and operation of the first telecom satellites, which can matter over a multi-quarter rollout period. A prior April 8, 2026 article also shows Open Cosmos spacecraft being used in the Orpheus UK military mission, adding defense-adjacent relevance. These dates are source dates extracted from the article summaries. Evidence
Caveats: Evidence is external article context and weak-context rows, not direct positive events. Same-article repeated rows are not independent confirmation. |
| 95 | Orbital lowweak | Opp 4 Risk 3 | Thesis: Risk is also meaningful because the same article describes an early-stage startup with only a $5 million pre-seed raise pursuing an extremely ambitious plan involving an in-orbit demo next year and more than 100,000 orbital data centers, which raises execution and scale risk, although this is supporting article context rather than direct adverse evidence, June 10, 2026). Why now: The recency is relatively fresh: the is based on June 10, 2026, inside the 90-day recent evidence window, and it frames both new capital and a next-year demo as near-to-medium-term strategic milestones. Evidence
Caveats: All retained evidence is weak context supporting article context; there is no direct positive event/fact available. Same-article repeated rows are not independent confirmation. The opportunity case depends on an early-stage roadmap and financing announcement; commercial traction is not directly evidenced in retained rows. |
| 96 | Orbital Recovery Crew lowweak | Opp 3 Risk 3 | Thesis: Risk is also material because the evidence is limited to the company's own site and supporting article context, with no independent retained event evidence for contracts, missions, financing, customers, or regulatory outcomes; the same page also conditions service availability on manifest availability and continuing cooperation of regulatory bodies. Why now: The only retained evidence is a page with May 21, 2026, within the 90-day window, indicating recent discoverable claims of operations and service scope, but not a third-party validated catalyst. Evidence
Caveats: Evidence is company-site article context, not independent confirmation. No direct positive or negative dated events are available. Same-article repeated rows are not independent confirmation. |
| 97 | Overview Energy lowweak | Opp 4 Risk 3 | Thesis: The technology area appears highly ambitious and execution-sensitive, but no direct negative evidence is provided in the reviewed sources. Why now: The likely catalyst is the reported Air Force contract, yet the reviewed sources gives no retained article summary or evidence row to establish recency or contract scale. Caveats: Phase2 membership rationale references: but no article summary or evidence are available. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 98 | Pacific Defense lowweak | Opp 4 Risk 3 | Thesis: Despite the favorable context, the reviewed sources contain no post-recent evidence window evidence, no -backed article summary, and no fresh proof of follow-on contracts or operational success after the demo; that limits conviction and leaves execution risk unresolved. Why now: The company appears more advanced than several peers because the reviewed sources references an on-orbit demo under contract, but there is no citable recency signal beyond membership support article ID: and no available evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary for citation. Opportunity score is relative within a weak-evidence batch, not high absolute conviction. |
| 99 | Payload Aerospace, S.A. lowweak | Opp 2 Risk 3 | Thesis: Main risk is evidence opacity and recency uncertainty rather than documented adverse events. The reviewed sources show one article considered but zero article IDs after recent evidence window and zero evidence available after recent evidence window, so business-state visibility is poor. Why now: Why now is weak because the reviewed sources' coverage debug shows zero article IDs after the March 29, 2026 cutoff and zero evidence after recent evidence window; any older fundraising context may no longer capture current business state. See support references listing article in the membership rationale, but no or article detail is provided in the reviewed sources, so recency and context cannot be independently assessed. Caveats: No -bearing article detail is provided for the fundraising support article, so factual claims beyond the membership rationale cannot be expanded. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0, limiting confidence. |
| 100 | Planet Labs PBC lowweak | Opp 3 Risk 3 | Thesis: Risk is moderate because the reviewed sources lack recent direct evidence on contracts, growth, financing, or setbacks, leaving the current business trajectory uncertain. Why now: Why-now is weak: the only in-window evidence is an April 5, 2026 startup-listing article describing Planet as operating its own satellite constellation and geospatial analytics platform, which is durable context but not a clear catalyst. Evidence
Caveats: Evidence is only supporting article context, not direct company event or fact evidence with strong materiality. No direct positive or negative dated events are available. This is a low-conviction watchlist name in these reviewed sources. |